Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4252W HIGH $5.45
Volume
1.38 M
Value Traded
4.93 M
Short % Float
14.32%
+1.57%Week
-28.37%1 Month
-33.5%3 Month
-25.5%6 Month
-93.17%5 Year
-87.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
285.96 M
EPS (TTM)
-0.16
P/E Ratio
-
Ent. Value
1.67 M
Total Shares
109.77 M
Float Shares
103.66 M
Insiders
5.57%
Institutions
91.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RCKT Catalyst Timeline
Dated clinical, regulatory and corporate events for Rocket Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rocket Pharmaceuticals, Inc.
329Total events
9Upcoming
91Tier-1 (high impact)
2014 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Debt Royalty FinancingCorporate
Rocket enters up to $150M credit facility with Hercules Capital
●Additional DataRP-A501Clinical Data
Original-dose Phase 2 results: three of four patients achieved at least 10% LV mass index reduction
Danon diseasesource ↗
▲Long Term DataRP-A501Clinical Data
Phase 1 long-term follow-up data at approximately three to seven years
Danon diseasesource ↗
▲Safety Data UpdateRP-A501Clinical Data
First three patients treated at recalibrated dose completed initial observation period without TMA or capillary leak syndrome
Danon diseasesource ↗
▲FDA Feedback ReceivedRP-A501FDA Meeting
FDA confirms alignment on continued enrollment/dosing and pivotal elements of Phase 2 RP-A501 trial in Danon disease
Danon diseasesource ↗
▲Safety Data UpdateRP-A501Clinical Data
Positive clinical safety update from initial three patients treated with RP-A501 under modified Phase 2 protocol
Danon diseasesource ↗
●Quarterly UpdateCorporate
Rocket reported financial and operational results for the second quarter ended June 30, 2026
▲PRV SoldDesignation
Rocket closed sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $180 million
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
▲FDA ApprovalKRESLADIApprovedFDA Decision
KRESLADI granted FDA accelerated approval
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
▲PRV SoldDesignation
Rare Pediatric Disease Priority Review Voucher monetized for $180 million
▲First Patient DosedRP-A701Trial
Dosing of first patient in Phase 1 study of RP-A701 for BAG3-DCM anticipated in mid-2026
BAG3-related dilated cardiomyopathysource ↗
▲Safety Data UpdateRP-A501Clinical Data
All three initial RP-A501 patients completed protocol-defined safety observation period with no TMA, CLS or other significant safety concerns
Danon diseasesource ↗
▲FDA ApprovalKRESLADIApprovedFDA Decision
FDA granted accelerated approval of KRESLADI (marnetegragene autotemcel) for severe LAD-I
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
◆PDUFA DateKRESLADIApprovedRegulatory Filing
PDUFA date for KRESLADI for severe LAD-I
severe LAD-Isource ↗
▲FDA ApprovalKRESLADIApprovedFDA Decision
FDA approval of KRESLADI for pediatric patients with severe LAD-I
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
▲PRV GrantedKRESLADIApprovedDesignation
FDA granted Rare Pediatric Disease Priority Review Voucher
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
▲Accelerated ApprovalKRESLADIApprovedFDA Decision
Accelerated approval granted based on increase in neutrophil CD18 and CD11a surface expression
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
◆Oral PresentationPresentation
Rocket Pharmaceuticals presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Trial PausedRP-A501Trial
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026
Danon diseasesource ↗
▲Enrollment UpdateRP-A501Trial
Dosing reinitiated in initial three-patient cohort of pivotal Phase 2 study
Danon diseasesource ↗
▲Trial InitiationRP-A501Trial
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume
Danon diseasesource ↗
▼Trial PausedRP-A501Trial
Pivotal Phase 2 trial of RP-A501 for Danon disease paused
Danon diseasesource ↗
◆Management ChangeCorporate
Appointment of Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer
◆Trial InitiationRP-A601Trial
Advancing RP-A601 toward pivotal Phase 2 study in PKP2-ACM
PKP2-ACMsource ↗
◆Trial InitiationRP-A701Trial
Preparing RP-A701 for first-in-human evaluation in BAG3-DCM
BAG3-DCMsource ↗
▲FDA Filing AcceptedKRESLADIApprovedRegulatory Filing
FDA acceptance of BLA resubmission for KRESLADI
severe Leukocyte Adhesion Deficiency-I (LAD-I)source ↗
▲Clinical Hold LiftedRP-A501IND
FDA lifts clinical hold on pivotal Phase 2 trial of RP-A501 for Danon disease
Danon diseasesource ↗
●Enrollment UpdateRP-A501Trial
Six patients treated in Phase 2 study to date; three additional patients to be treated at lower dose
Danon diseasesource ↗
▲Fast Track DesignationRP-A701Designation
FDA Fast Track designation received for RP-A701
BAG3-DCMsource ↗
▼Program DiscontinuationCorporate
Pausing additional investments in PKD program; exploring strategic alternatives
Pyruvate Kinase Deficiencysource ↗
◆FDA Feedback ReceivedRP-A501FDA Meeting
Regulatory alignment to resolve clinical hold for RP-A501 in progress
Danon diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How RCKT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-27 | KRESLADI™ | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$12M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 75%
Micro Cap(rank 494 of 658)
Percentile Rank
Rocket Pharmaceuticals, Inc. faces pipeline headwinds (28/100), with $60M risk-adjusted pipeline value, led by RP-L102 in Fanconi Anemia Complementation Group A (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RP-L102 Monoclonal antibodyNCT04248439 | Fanconi Anemia Complementation Group A | Phase 2 | ACTIVE NOT_RECRUITING | 5 | May 5, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every RCKT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RP-A501 Fast TrackRMATOrphan+1 | Danon disease | Phase 2 | 2026-10-07 | 12 male patients receiving commercial-grade RP-A501; at least seven patients to meet both response criteria at 12 months; all six patients in the principal Phase 1 analysis demonstrated myocardial LAMP2 protein expression and at least a 10% reduction in left ventricular mass index; left ventricular mass index was below baseline in five of six patients; reductions of at least 10% in four patients; Three of four patients with longitudinal efficacy assessments achieved at least a 10% reduction in left ventricular mass indexRead More | Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor WebinarRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wilson MartinOfficer (General Counsel) | Sell | -75,364 598,489 held | $3.40 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RCKT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.5 % (-16.7 %) | 60.49 M | 17.69 M |
RCKT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RCKT ranks across every disease it competes in
Competitive Position is a premium feature
See how RCKT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRCKT News
RCKT▼ -1.1%today
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Rocket Pharmaceuticals provided an update on its FDA-aligned pivotal Phase 2 trial for RP-A501 during an investor webinar focused on Danon disease. Key findings included a clear path to trial completion and sustained biological activity from Phase 1 follow-ups. The company aims to advance its genetic medicines for rare diseases.
Read more →RCKT▼ -1.1%today
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Rocket Pharmaceuticals has secured a strategic credit facility of up to $150 million from Hercules Capital. This agreement is expected to enhance Rocket's financial position and provide necessary capital to support its ongoing initiatives. The funding will aid in advancing the company's efforts in genetic medicines for rare diseases.
Read more →RCKTRocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals has received FDA alignment for the pivotal Phase 2 trial of RP-A501, aimed at treating Danon disease. The announcement includes approval for continued patient enrollment and dosing, along with a recalibrated dose to optimize treatment outcomes. This development marks a significant step forward in the company's efforts to address this rare genetic disorder.
Read more →RCKTRocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. will participate in the 2026 Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in New York. CEO Gaurav Shah, M.D., will engage in fireside chats at these events. This participation underscores the company's commitment to advancing genetic medicines for rare diseases.
Read more →RCKTRocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals reported strong financial results for Q2 2026, highlighting the approval of KRESLADI, which enhances their position in the genetic medicines market. The company is focused on addressing inherited cardiovascular disorders and continues to make significant progress in its operational goals.
Read more →RCKT▲ +9.6%on this news
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Rocket Pharmaceuticals has reported a positive clinical safety update from the first three patients treated with RP-A501 under a modified Phase 2 protocol for Danon disease. The early safety results are encouraging, indicating the potential of RP-A501 in addressing this rare genetic disorder. This update marks a significant step in the ongoing global trial.
Read more →RCKTRocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Rocket Pharmaceuticals has successfully closed the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million. This sale is expected to provide substantial funding for the company's initiatives focused on pediatric diseases. The transaction highlights the value of such vouchers in accelerating drug development for rare conditions.
Read more →RCKTRocket Pharmaceuticals to Participate in Upcoming June 2026 Investor Conferences
Rocket Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. CEO Gaurav Shah will engage in a fireside chat and management will hold investor meetings at both events. Webcasts of the presentations will be available on the company's website.
Read more →RCKTRocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals has released its financial results for the first quarter of 2026, highlighting recent progress in its operations. The report provides insights into the company's financial performance and developments during this period. Further details regarding specific advancements or challenges were not disclosed in the article.
Read more →RCKTRocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Rocket Pharmaceuticals has announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. This transaction is expected to significantly strengthen the company's financial position, allowing for further investment in its pipeline of genetic therapies aimed at rare disorders. The PRV was awarded by the U.S. Food and Drug Administration.
Read more →RCKT▼ -19.6%on this news
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals has received FDA approval for KRESLADI™, the first gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). This approval is based on clinical data showing increased neutrophil surface expression. The company also received a Rare Pediatric Disease Priority Review Voucher, which it plans to monetize. KRESLADI aims to address a critical need in treating this ultra-rare genetic disorder.
Read more →RCKT▲ +10.6%on this news
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical pipeline. The pivotal Phase 2 trial for RP-A501 in Danon disease is set to resume in the first half of 2026, while the PDUFA date for KRESLADI™ is scheduled for March 28, 2026. The company also anticipates dosing the first patient in a Phase 1 study for RP-A701 in mid-2026, supported by a strong cash position.
Read more →RCKTRocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rocket Pharmaceuticals will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with CEO Gaurav Shah presenting on January 14. The company focuses on genetic therapies for rare disorders and has several late-stage clinical programs. A webcast of the presentation will be available on their website.
Read more →RCKTRocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. has reported its financial results for the third quarter of 2025 and highlighted key operational updates. The company confirmed the resumption of its Phase 2 pivotal study for RP-A501 targeting Danon disease, scheduled to continue in the first half of 2026. Additionally, KRESLADI is set to be evaluated by the FDA with a PDUFA date of March 28, 2026. Rocket's leadership team has seen new appointments, and its solid financial reserves extend operational capacity into the second quarter of 2027.
Read more →RCKT▲ +23.1%on this news
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals announced that the FDA has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI, a gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). The PDUFA target action date is set for March 28, 2026. Clinical trials showed that KRESLADI was well tolerated, meeting all primary and secondary endpoints with a 100% survival rate among patients 12 months post-infusion. If approved, Rocket will also be eligible for a Rare Pediatric Disease Priority Review Voucher.
Read more →RCKT▲ +28.9%on this news
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
Rocket Pharmaceuticals announced that the FDA has lifted the clinical hold on its pivotal Phase 2 trial for RP-A501, aimed at treating Danon disease. The hold was removed in under three months, validating the company's efforts to address FDA concerns promptly. The trial will now resume with a recalibrated dosage strategy and modified immunomodulatory regimen. With six patients already treated, Rocket anticipates further updates as more patients receive the therapy.
Read more →RCKTRocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals reported its financial results for Q2 2025, highlighting key advancements in its gene therapy pipeline. The company is focusing on RP-A501 for Danon disease, RP-A601 for PKP2-ACM, and RP-A701 for BAG3-DCM, with regulatory designations aiding their progress. Improvements include a significant cash reserve for operational needs extending into 2027. However, a restructuring plan is set to reduce the workforce by about 30%, signaling an adjustment in strategic priorities and resource allocation.
Read more →RCKTRocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
Rocket Pharmaceuticals has announced a strategic corporate reorganization aimed at prioritizing its cardiovascular programs centered on its AAV platform. The restructuring will involve a workforce reduction of around 30% and is intended to decrease operating expenses by approximately 25%, extending the company's cash runway to mid-2027. Programs targeting Danon disease, PKP2-ACM, and BAG3-DCM will be emphasized, while anticipated delays are noted for Fanconi Anemia and Pyruvate Kinase Deficiency programs. This shift reflects Rocket's focus on high-opportunity areas within its pipeline.
Read more →About Rocket Pharmaceuticals, Inc.
Headquarters350 FIFTH AVENUE, NEW YORK, NY, 10118
BIOPHARMAWATCH ELITE PLUS
Trade the next RCKT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime